Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

In a recent filing with the Securities and Exchange Commission, Vertex (NASDAQ:VRTX), Inc. (NASDAQ:VERX) disclosed that the ITEM SECOND IRR. TRUST FBO KYLE R. WESTPHAL, a significant shareholder, ...

This was the stock's fourth consecutive day of gains.

Shares have been on the move with the stock up 5.8% over the past month. The stock hit a new 52-week high of $58.22 in the previous session. Vertex has gained 6.2% since the start of the year compared ...

The U.S. Bankruptcy Court for the Southern District of Texas allowed the company to exit bankruptcy as a privately-held company under the ownership of lenders. Those lenders include funds managed by ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

Vertex Energy has emerged as a privately held company after emerging from Chapter 11 bankruptcy. The company company filed for protections in 2024 after spending on equipment ...

Vertex specializes in corporate tax compliance software, targeting a $22B global TAM with a focus on enterprise and SMB ...

I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...

This non-opioid pain drug targets a multibillion-dollar market. Vertex also has multiple other catalysts on the way in 2025 ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $428, representing a +0.03% change from its previous close.